ARMISTICE CAPITAL, LLC - Q4 2017 holdings

$1 Billion is the total value of ARMISTICE CAPITAL, LLC's 67 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 147.6% .

 Value Shares↓ Weighting
CERC BuyCERECOR INC$51,360,000
+277.6%
16,050,000
+0.3%
5.12%
+219.7%
HAIN BuyHAIN CELESTIAL GROUP INCcall$46,629,000
+25.9%
1,100,000
+22.2%
4.65%
+6.6%
VNDA BuyVANDA PHARMACEUTICALS INC$40,706,000
+48.4%
2,678,000
+74.8%
4.06%
+25.7%
UTHR BuyUNITED THERAPEUTICS CORP DEL$29,590,000
+68.3%
200,000
+33.3%
2.95%
+42.4%
ENR BuyENERGIZER HLDGS INC NEW$29,364,000
+21.7%
612,000
+16.8%
2.93%
+3.0%
HBI BuyHANESBRANDS INC$29,274,000
+180.2%
1,400,000
+230.2%
2.92%
+137.1%
CPB BuyCAMPBELL SOUP CO$29,251,000
+111.1%
608,000
+105.4%
2.92%
+78.6%
PZZA NewPAPA JOHNS INTL INCcall$25,250,000450,000
+100.0%
2.52%
POST NewPOST HLDGS INC$24,720,000312,000
+100.0%
2.46%
PLYA BuyPLAYA HOTELS & RESORTS NV$23,997,000
+41.3%
2,224,000
+36.6%
2.39%
+19.6%
CMG NewCHIPOTLE MEXICAN GRILL INC$22,544,00078,000
+100.0%
2.25%
SBBP BuySTRONGBRIDGE BIOPHARMA PLC$20,808,000
+78.0%
2,870,000
+69.4%
2.08%
+50.7%
UAA NewUNDER ARMOUR INCcl a$20,202,0001,400,000
+100.0%
2.01%
HOG NewHARLEY DAVIDSON INC$19,538,000384,000
+100.0%
1.95%
CAKE BuyCHEESECAKE FACTORY INC$19,272,000
+41.2%
400,000
+23.5%
1.92%
+19.5%
ATRS BuyANTARES PHARMA INC$15,124,000
+11.1%
7,600,000
+81.0%
1.51%
-5.9%
PCRX BuyPACIRA PHARMACEUTICALS INC$14,973,000
+38.5%
328,000
+13.9%
1.49%
+17.2%
KORS NewMICHAEL KORS HLDGS LTD$14,856,000236,000
+100.0%
1.48%
GSK NewGLAXOSMITHKLINE PLCsponsored adr$14,614,000412,000
+100.0%
1.46%
HZNP BuyHORIZON PHARMA PLC$14,600,000
+43.9%
1,000,000
+25.0%
1.46%
+21.8%
CVS NewCVS HEALTH CORP$14,500,000200,000
+100.0%
1.45%
GME NewGAMESTOP CORP NEWcl a$14,360,000800,000
+100.0%
1.43%
BJRI BuyBJS RESTAURANTS INC$13,978,000
+53.0%
384,000
+28.0%
1.39%
+29.6%
GPS NewGAP INC DEL$13,624,000400,000
+100.0%
1.36%
AET NewAETNA INC NEW$11,545,00064,000
+100.0%
1.15%
OPHT BuyOPHTHOTECH CORP$10,764,000
+13.5%
3,450,000
+2.6%
1.07%
-3.9%
PAG BuyPENSKE AUTOMOTIVE GRP INC$10,144,000
+72.0%
212,000
+71.0%
1.01%
+45.5%
EBAY NewEBAY INC$9,963,000264,000
+100.0%
0.99%
SHPG NewSHIRE PLCsponsored adr$9,928,00064,000
+100.0%
0.99%
PZZA NewPAPA JOHNS INTL INC$9,651,000172,000
+100.0%
0.96%
NewPERNIX THERAPEUTICS HLDGS INdbcv 4.250% 4/0$9,175,00021,760,000
+100.0%
0.92%
ALIM BuyALIMERA SCIENCES INC$9,060,000
+7.1%
6,812,000
+8.7%
0.90%
-9.3%
TPR NewTAPESTRY INC$9,023,000204,000
+100.0%
0.90%
BBBY NewBED BATH & BEYOND INC$6,597,000300,000
+100.0%
0.66%
AMZN NewAMAZON COM INC$5,847,0005,000
+100.0%
0.58%
DKS NewDICKS SPORTING GOODS INCcall$5,748,000200,000
+100.0%
0.57%
W NewWAYFAIR INCcl a$5,458,00068,000
+100.0%
0.54%
EIGR NewEIGER BIOPHARMACEUTICALS INC$5,357,000384,000
+100.0%
0.53%
ASMB NewASSEMBLY BIOSCIENCES INC$5,068,000112,000
+100.0%
0.50%
ZFGN BuyZAFGEN INC$4,324,000
+223.2%
936,000
+146.3%
0.43%
+172.8%
APRN NewBLUE APRON HLDGS INCcl a$4,030,0001,000,000
+100.0%
0.40%
VICL NewVICAL INC$3,660,0002,000,000
+100.0%
0.36%
ATNM BuyACTINIUM PHARMACEUTICALS INC$2,962,000
+17.5%
4,464,000
+1.9%
0.30%
-0.7%
ATEC BuyALPHATEC HOLDINGS INC$2,071,000
+39.2%
778,414
+18.2%
0.21%
+18.3%
AVEO NewAVEO PHARMACEUTICALS INC$1,674,000600,000
+100.0%
0.17%
IPCI NewINTELLIPHARMACEUTICS INTL IN$1,549,0001,936,000
+100.0%
0.15%
DYNT BuyDYNATRONICS CORP$1,505,000
+30.4%
521,891
+2.3%
0.15%
+10.3%
ANTH NewANTHERA PHARMACEUTICALS INC$1,269,000768,915
+100.0%
0.13%
AYTU NewAYTU BIOSCIENCE INC$818,000366,667
+100.0%
0.08%
CHEK NewCHECK CAP LTD$651,000748,000
+100.0%
0.06%
FCSC NewFIBROCELL SCIENCE INC$393,000613,896
+100.0%
0.04%
BPMX NewBIOPHARMX CORP$382,0003,470,000
+100.0%
0.04%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2018-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ENANTA PHARMACEUTICALS INC30Q3 20232.7%
SPDR S&P 500 ETF TR28Q3 202329.5%
MADRIGAL PHARMACEUTICALS INC27Q3 20232.9%
VANDA PHARMACEUTICALS INC26Q3 20219.4%
REGENERON PHARMACEUTICALS25Q3 20233.2%
ENERGIZER HLDGS INC NEW22Q2 20233.7%
ANTARES PHARMA INC21Q3 20206.6%
INCYTE CORP21Q3 20232.8%
VOYAGER THERAPEUTICS INC21Q3 20232.0%
BLUEBIRD BIO INC20Q4 20211.8%

View ARMISTICE CAPITAL, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ARMISTICE CAPITAL, LLC Q4 2017 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Avalo Therapeutics, Inc.June 28, 2023588,8504.7%
Addex Therapeutics Ltd.February 16, 2023675,2955.0%
Arcadia Biosciences, Inc.February 14, 20232,675,40910.0%
Avinger IncFebruary 14, 2023789,40010.0%
Baudax Bio, Inc.February 14, 20231,165,7095.0%
BIORA THERAPEUTICS, INC.February 14, 202312,989,6485.7%
Bit Digital, IncFebruary 14, 20233,161,8893.7%
Bruush Oral Care Inc.February 14, 20231,122,92210.0%
CATALYST PHARMACEUTICALS, INC.Sold outFebruary 14, 202300.0%
Clarus Therapeutics Holdings, Inc.February 14, 20232,732,1695.0%

View ARMISTICE CAPITAL, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View ARMISTICE CAPITAL, LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export ARMISTICE CAPITAL, LLC's holdings